Apolipoprotein B48: a novel marker of metabolic risk in overweight children?

M M U Nzekwu1, G D C Ball, M M Jetha

  • 1Alberta Institute For Human Nutrition, University of Alberta, Edmonton, Alberta, Canada.

Insights

Elevated fasting apoB48 levels were found in overweight children, correlating with insulin resistance and visceral fat. This suggests apoB48 may be an early marker for cardiovascular disease risk in this population.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Disease Risk Factors
  • Metabolic Health

Background:

  • Clinical studies link insulin resistance, dyslipidemia, visceral fat, and intestinally derived lipoproteins (apoB48) to cardiovascular disease (CVD) risk in adults.
  • Limited data exists on postprandial dyslipidemia and related markers in overweight children.

Purpose of the Study:

  • To compare fasting apolipoprotein B48 (apoB48) levels with insulin resistance (HOMA-IR), lipid profiles, and visceral adipose tissue (VAT) in overweight pre-pubertal children.
  • To investigate apoB48 as a potential early indicator of metabolic dysfunction in pediatric obesity.

Main Methods:

  • Recruitment of pre-pubertal overweight boys and girls from Edmonton, Alberta.
  • Body composition assessment using dual-energy X-ray absorptiometry and MRI.
  • Quantification of fasting apoB48 via SDS/PAGE immunoblotting; measurement of insulin, glucose, TC, TAG, LDL, and HDL via calorimetric assay.

Main Results:

  • Overweight children exhibited fasting apoB48 concentrations exceeding the normal adult range.
  • Fasting apoB48 showed significant positive associations with HOMA-IR and triacylglycerol (TAG) levels.
  • Preliminary MRI analysis indicated a positive relationship between apoB48 and visceral adipose tissue (VAT) volume.

Conclusions:

  • This study is the first to report apoB48 concentrations in overweight pre-pubertal children.
  • Elevated fasting apoB48 in this cohort suggests a potential link to insulin resistance and increased visceral fat.
  • Further research is warranted to explore apoB48's role in early CVD risk stratification in pediatric obesity.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...